Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.11. | Bicara Therapeutics GAAP EPS of -$1.60 | 1 | Seeking Alpha | ||
12.11. | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | 108 | GlobeNewswire (Europe) | On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with... ► Artikel lesen | |
06.11. | RODMAN&RENSHAW Upgrades Bicara Therapeutics (NASDAQ:BCAX) to "Strong-Buy" | 1 | MarketBeat | ||
BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
05.11. | Bicara Therapeutics-Aktie erhält Kaufempfehlung von H.C. Wainwright aufgrund vielversprechenden Wirkstoffs | 2 | Investing.com Deutsch | ||
05.11. | Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset | 1 | Investing.com | ||
24.10. | Biocon accused of committing IP theft to create cancer biotech Bicara | 1 | FierceBiotech | ||
08.10. | Cantor Fitzgerald stuft Bicara Therapeutics mit "Overweight" ein | 1 | Investing.com Deutsch | ||
08.10. | Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating | 1 | Investing.com | ||
08.10. | Bicara Therapeutics stock sees upside with lead drug potential, says Stifel | 1 | Investing.com | ||
08.10. | Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic | 5 | Investing.com | ||
08.10. | Bicara-Aktie bereit für Wachstum mit Übergang zur Spätphase, Morgan Stanley optimistisch | 4 | Investing.com Deutsch | ||
17.09. | Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity | 2 | Pharmaceutical Technology | ||
16.09. | Bicara Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.09. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 107 | GlobeNewswire (Europe) | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients... ► Artikel lesen | |
13.09. | Bicara Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
13.09. | Bicara, MBX Bio lead gainers as biotech trio makes trading debut | 2 | Seeking Alpha | ||
13.09. | Bicara Therapeutics Opens at $26.25, Upsized IPO Priced at $18 | 2 | Investing.com | ||
13.09. | Oncology biotech Bicara Therapeutics prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
13.09. | Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs | - | FierceBiotech | ||
13.09. | Bicara Leads Trio of US Biotech IPOs Raising $703 Million | 1 | BNN Bloomberg |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
EVOTEC | 9,925 | +0,20 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
QIAGEN | 39,905 | +2,74 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |